Mirna Chehade, MD, MPH, discusses ongoing trials for emerging therapies in eosinophilic esophagitis (EoE), her views on the use of combination therapies, and the importance of shared decision-making for the chronic management of EoE throughout the different phases of a patient’s life.
This is a video synopsis/summary of an Insights involving Mirna Chehade, MD, MPH.
Chehade discusses promising emerging treatments for eosinophilic esophagitis (EoE), including biologics like dupilumab, tezepelumab, and barzolvolimab. Additional options like APT-1011 and etrasimod show potential. The impact on prescribing practices will depend on efficacy, safety, and observed side effects in trials.
For pediatric patients, Chehade recommends starting with a single therapy and cautious use of combination therapies. She emphasizes involving both child and parent in decision-making, addressing medical, nutritional, and psychosocial well-being throughout different life phases with EoE.
Managing EoE requires a comprehensive approach due to its chronic nature, ensuring support for patients in various life stages. The evolving landscape of emerging therapies brings optimism for improved EoE management.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.